Regulatory Qualification Program

About Xellar Biosystems

Xellar Biosystems, founded in 2019 and based in Boston, is developing an innovative organ-on-chip platform combined with artificial intelligence to improve the predictive accuracy of preclinical drug testing. The company's E.P.I.C. Platform (Engineering, Preclinical, Imaging, Computation) creates a closed-loop feedback system for scalable exploration of human biology, aiming to address critical limitations of 2D cultures, 3D organoids, and animal models. By providing physiologically realistic human organ models, Xellar seeks to de-risk drug development, shorten timelines, and promote regulatory adoption of human-relevant testing methods.